How Peptide Doping Is Detected: Mass Spec and Biomarkers

WADA and Peptide Doping

54 peptides

Modern anti-doping screening assays can simultaneously detect 54 prohibited small peptides and related substances in a single urine sample using LC-HRMS.

Chang et al., Journal of Chromatography A, 2021

Chang et al., Journal of Chromatography A, 2021

View as image

Peptides are among the hardest substances to detect in doping control. They are natural in origin (or closely mimic natural molecules), degrade rapidly in biological samples, circulate at picomolar concentrations, and are cleared from urine within hours to days. Despite these challenges, anti-doping laboratories have developed detection methods that can identify over 54 banned peptides simultaneously from a single urine sample at concentrations below 1 nanogram per milliliter.^[1] This article explains the detection technologies, the analytical challenges unique to peptides, and how anti-doping science stays ahead of an expanding prohibited list. For the rationale behind which peptides are banned, see our pillar article on why WADA bans peptides.

Why peptides are hard to detect

Small peptides present unique analytical challenges that make them fundamentally different from detecting steroids, stimulants, or other traditional doping agents:

Rapid degradation. Peptides are broken down by endogenous proteases in blood and urine. A GHRP injected subcutaneously may circulate for only minutes before enzymatic degradation produces fragments that no longer match the parent compound's mass spectrum.

Low circulating concentrations. Effective doses of many banned peptides produce plasma concentrations in the picomolar to low nanomolar range. By the time the peptide and its metabolites reach urine, concentrations may be sub-nanogram per milliliter.

Short detection windows. Many peptides are cleared from urine within 6-24 hours after administration. Compared to anabolic steroids (detectable for weeks to months), the window for catching peptide use is extremely narrow.

Structural similarity to endogenous peptides. Some banned peptides differ from natural human peptides by only one or two amino acids. Distinguishing exogenous GHRP-2 from endogenous ghrelin fragments requires mass accuracy that conventional immunoassays cannot achieve.

Expanding prohibited list. WADA's prohibited list includes an increasing number of peptides each year. Labs must develop and validate new methods for each addition while maintaining sensitivity for existing targets.

The detection platform: LC-HRMS

Liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS) has become the standard detection platform for peptide doping analysis.^[1]

Liquid chromatography (LC) separates peptides in a urine extract by passing them through a column packed with particles that interact differently with different peptide structures. Peptides elute from the column at different retention times based on their hydrophobicity and charge.

Electrospray ionization (ESI) converts the liquid-phase peptides into gas-phase ions as they exit the LC column. The ions are then introduced into the mass spectrometer.

High-resolution mass spectrometry (HRMS) measures the mass-to-charge ratio of each ion with accuracy to four or more decimal places. This precision enables unambiguous identification: a peptide with a measured mass of 657.3312 Da can be distinguished from a different peptide at 657.3356 Da.

Parallel reaction monitoring (PRM) adds specificity by fragmenting parent ions and detecting specific daughter ions (transition fragments). This means even if two peptides have similar parent masses, their fragmentation patterns serve as unique fingerprints.^[1]

Chang et al.'s 2021 method demonstrated this platform's power: a single 30-minute LC-HRMS run screens for 54 prohibited peptides in urine with limits of detection as low as 0.20 ng/mL. Over 5,000 routine doping control samples were analyzed with zero false positives and zero false negatives.^[1]

Sample preparation: getting peptides out of urine

Raw urine contains thousands of compounds that interfere with peptide detection. Sample preparation steps isolate and concentrate target peptides before LC-HRMS analysis.

Solid phase extraction (SPE) is the most common approach. Urine is passed through a cartridge containing particles that selectively bind peptides while washing away salts, metabolites, and other matrix components. Weak cation exchange (WCX) SPE cartridges are particularly effective for cationic peptides like GHRPs.^[1]

Immunoaffinity purification uses antibodies specific to target peptides or peptide classes to selectively capture them from urine. Thevis et al. pioneered this approach for peptide hormone screening, using antibodies against GHRPs to concentrate these analytes 10 to 100-fold before mass spectrometry.^[2] The technique dramatically lowers detection limits, making it possible to catch peptide use even at the tail end of the detection window.

Alkaline pre-activation of SPE cartridges (as described by Chang et al.) improves recovery of small peptides that are poorly retained by conventional extraction methods.

GHRP and GH secretagogue detection

Growth hormone releasing peptides and ghrelin receptor agonists represent a high-priority detection target for anti-doping labs. Judak et al.'s 2021 method simultaneously detects 10 GH secretagogues in human urine:^[3]

• GHRPs: alexamorelin, GHRP-1, GHRP-2, GHRP-4, GHRP-5, GHRP-6, hexarelin
• Non-peptide GH secretagogues: anamorelin, ibutamoren (MK-677), ipamorelin

Each compound has a unique mass spectrum and retention time, allowing unambiguous identification. For why GH secretagogues are specifically prohibited and the pharmacological reasoning behind the ban, see our dedicated article.

Biomarker testing: the indirect approach

Direct detection of peptides works when samples are collected within the narrow detection window. When that window closes, anti-doping labs turn to biomarker testing, which measures the downstream biological effects of peptide use rather than the peptide itself.

The GH-2000 biomarker test measures the ratio of insulin-like growth factor-1 (IGF-1) to procollagen type III N-terminal peptide (P-III-NP) in blood. GH and GH secretagogue use elevates both markers, and the ratio remains abnormal for days to weeks after the peptide itself is no longer detectable.

The Athlete Biological Passport (ABP) extends this concept by tracking multiple biomarkers over time for each athlete. Longitudinal monitoring creates an individual baseline, and deviations from that baseline trigger suspicion even without detecting a specific banned substance. For how the ABP catches peptide users through longitudinal data, see our sibling article.

Synthetic reference standards

Accurate peptide detection requires reference standards: pure samples of each banned peptide used to calibrate instruments and confirm identifications. Gomez-Guerrero et al.'s 2022 review highlighted that custom synthesis of reference peptides is essential to anti-doping method development.^[4]

For novel peptides that appear on underground markets before they reach the WADA prohibited list, reference standards must be synthesized from scratch based on structural information from seizures, online vendor analysis, or published research. This means anti-doping labs effectively reverse-engineer new peptide drugs to develop detection methods, sometimes before the peptides are even formally prohibited.

Detection windows by peptide class

Detection windows vary by peptide, route of administration, dose, and individual metabolism:

The shorter the detection window, the more reliant anti-doping enforcement becomes on out-of-competition testing and biomarker profiling. For the anti-doping status of BPC-157 and TB-500, see our dedicated article.

The arms race: staying ahead

Anti-doping peptide detection operates in a perpetual arms race. New synthetic peptides appear on gray markets faster than WADA can add them to the prohibited list and labs can develop validated detection methods. Ho et al.'s early work on doping control analysis of small peptides established foundational methods that have been iteratively refined over the past decade.^[5]

Current strategies to maintain detection capability include:

Retrospective analysis. Anti-doping laboratories store samples for up to 10 years. When a new detection method is developed, it can be applied retroactively to stored samples, potentially catching athletes who used a peptide before a detection method existed.

Untargeted screening. High-resolution mass spectrometry captures full-scan data on every compound in a sample. Even without knowing what to look for in advance, the data can be re-analyzed later when a new peptide threat is identified.

Intelligence-driven testing. Information from law enforcement, customs seizures, and online marketplace monitoring helps labs prioritize which new peptides to develop methods for.

For the latest on emerging peptide doping threats, see our sibling article.

The Bottom Line

Anti-doping laboratories detect banned peptides using LC-HRMS platforms that simultaneously screen for 54+ prohibited peptides in a single urine sample at sub-nanogram sensitivity. The primary challenges are peptides' rapid degradation, low circulating concentrations, and short detection windows (often under 24 hours). Immunoaffinity purification and optimized solid phase extraction concentrate target peptides before mass spectrometric identification. When direct detection windows close, biomarker tests (IGF-1/P-III-NP ratios) and the Athlete Biological Passport provide indirect evidence of GH secretagogue use. Retrospective sample analysis and untargeted HRMS screening give laboratories the ability to catch peptide doping even after new compounds appear on the market.

Frequently Asked Questions

How do anti-doping labs detect peptide use?

Anti-doping labs primarily use liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS). Urine samples undergo solid phase extraction or immunoaffinity purification to concentrate target peptides, then LC-HRMS identifies them by exact molecular mass and fragmentation pattern. Modern methods screen for 54+ banned peptides in a single run with detection limits as low as 0.2 ng/mL.

How long are peptides detectable in urine for doping tests?

Detection windows vary by peptide: GHRPs like GHRP-2 and GHRP-6 are detectable for 6-24 hours, ipamorelin for 12-36 hours, and oral MK-677 for 24-72 hours. When direct detection windows close, biomarker tests measuring IGF-1 and P-III-NP can indicate GH secretagogue use for days to weeks afterward.

Can mass spectrometry detect BPC-157?

BPC-157 detection methods are under active development by anti-doping laboratories, but validated routine screening methods are limited compared to well-established GHRP detection. The challenge is that BPC-157 degrades rapidly in biological samples and produces fragments that are difficult to distinguish from endogenous peptide metabolism products.

What is the GH-2000 biomarker test?

The GH-2000 test measures blood levels of IGF-1 and procollagen type III N-terminal peptide (P-III-NP) as indirect evidence of growth hormone or GH secretagogue use. Both markers remain elevated for days to weeks after the banned peptide itself has been cleared from the body, extending the effective detection window beyond direct urine testing.

Do anti-doping labs test for all WADA banned peptides?

WADA-accredited laboratories use validated screening methods that cover the most commonly abused peptides, including GHRPs, GH secretagogues, and selected other peptide hormones. Not every banned peptide has an equally sensitive detection method. Labs prioritize development of methods for peptides with the highest abuse potential and continuously expand their screening panels.

Can stored doping samples be retested for new peptides?

Yes. Anti-doping laboratories store athlete samples for up to 10 years. When new detection methods are developed for previously undetectable peptides, stored samples can be retrospectively analyzed. High-resolution mass spectrometry captures full-scan data that can be re-mined for new analytes without reprocessing the original sample.